Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cyprotex Announces a Collaborative Research Agreement with Pfizer

Published: Friday, November 02, 2012
Last Updated: Friday, November 02, 2012
Bookmark and Share
The deal extends over an eighteen month period and is split into two stages with the second stage being dependent on certain milestones being achieved.

The collaboration is a research-based project which the parties aim to evaluate, further develop, and improve several of Cyprotex’s proprietary offerings in the area of predictive toxicology.

Dr. Anthony Baxter, Cyprotex’s Chief Executive Officer, comments on the collaboration: “We are delighted to be able to continue our relationship with Pfizer. This collaborative research is beneficial for both companies and allows Cyprotex to remain at the forefront of new approaches in toxicology prediction. Predicting drug-induced toxicity is a challenging field, and we are making significant advances by combining our knowledge with that of our partners and clients.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cyprotex Appoints Dr Rob Elsby as Leader of Drug Transporter Team
Cyprotex PLC has appointed Dr Rob Elsby as Leader of its Drug Transporter Team.
Wednesday, March 18, 2015
Cyprotex Acquires CeeTox
Auquistion broadens toxicological assay and screening capabilities to the cosmetic and personal care industry.
Thursday, January 02, 2014
Cyprotex Launch Updated Drug-Drug Interaction Regulatory Guidance
Booklet to reflect the new FDA and EMA guidelines.
Friday, August 17, 2012
Sygnature Discovery and Cyprotex Extend Successful Strategic Alliance
The companies have announced they have entered into an extension of their highly successful partnership for a further 2 years.
Monday, December 19, 2011
Cyprotex Extends Cloe® Screen Mechanism-Based Inhibition Service to Include 4 Additional Cytochrome P450 Isoforms
New assays compliment the CYP3A4 isoform assay which was launched last year.
Friday, March 30, 2007
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Substance Can Potentially Postpone Aging
Researchers bridge the gap between two main aging theories - repairs to the DNA and poor functioning mitochondria.
Untangling Cause Of Memory Loss In Neurodegenerative Diseases
NIH-funded mouse study identifies a possible therapeutic target for a family of disorders.
New Model for Understanding Human Myeloma
Researchers develop mouse model where mice carry six human genes involved in human tumour growth.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
New Platform for Roundworms Could Speed Up Drug Delivery
Researchers have developed a large-scale in vitro drug discovery platform that could speed up scientific research.
"Junk" DNA Critical for Heart Function
Loss of noncoding elements of genome, known as enhancers, results in abnormalities of heart functions.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos